PRODUCT_WITH_CATEGORY
Medicines
Daiichi Sankyo is dedicated to creating new standards of care by leveraging our world-class science and technology. We currently have three innovative oncology medicines approved in the U.S. to treat certain patients with breast, lung and gastric cancer as well as acute myeloid leukemia and tenosynovial giant cell tumor. Our other U.S. medicines include those to treat thrombosis, stroke risk reduction and iron deficiency anemia.
Click to view Daiichi Sankyo medicines available in other countries:
WorldwideU.S. Medicines
ENHERTU®
(fam-trastuzumab deruxtecan-nxki)
See full prescribing Information, including boxed warnings and medication guide.
SAVAYSA®
(edoxaban) tablets
See full prescribing Information, including boxed warnings and medication guide.
TURALIO®
(pexidartinib)
See full prescribing Information, including boxed warning regarding liver toxicity and medication guide.
VANFLYTA®
(quizartinib)
See full prescribing Information, including boxed warning and medication guide.
Have a question about a medicine?
Please call the Daiichi Sankyo Contact Center at 1-877-4DS-PROD
(1-877-437-7763) if you have a question about any of our medicines or to report
any adverse reactions to our medicines. To report negative side effects of
prescription drugs to the FDA, visit www.fda.gov/medwatch